New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
06:45 EDTJNJ, GILDStocks with implied volatility movement; JNJ GILD
Stocks with implied volatility movement; Johnson & Johnson (JNJ), Gilead (GILD) according to iVolatility.
News For JNJ;GILD From The Last 14 Days
Check below for free stories on JNJ;GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 27, 2014
10:02 EDTGILDActive equity options trading on open
Subscribe for More Information
05:56 EDTGILDStocks with implied volatility movement; XRT GILD
Subscribe for More Information
August 26, 2014
16:02 EDTGILDOptions Update; August 26, 2014
iPath S&P 500 VIX Short-Term Futures up 27c to 27.69. Option volume leaders: AAPL TSLA TWTR AMZN GILD JNS NFLX according to Track Data.
11:44 EDTGILDOptions with increasing implied volatility
Options with increasing implied volatility: TLM CODE TRW GILD WTW PSEC
11:19 EDTGILDGilead added to short term buy list at Deutsche Bank
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
06:05 EDTGILDStocks with implied volatility movement; MCP GILD
Subscribe for More Information
August 25, 2014
16:00 EDTGILDOptions Update; August 25, 2014
Subscribe for More Information
12:19 EDTGILDOn The Fly: Midday Wrap
Subscribe for More Information
10:40 EDTGILDBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
08:27 EDTJNJJanssen Affiliate Cilag acquires Covagen, terms not disclosed
Subscribe for More Information
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
06:11 EDTGILDStocks with implied volatility movement; FOLD GILD
Stocks with implied volatility movement; Amicus Therapeutics (FOLD) 87, Gilead (GILD) 25 according to iVolatility.
August 22, 2014
11:17 EDTGILDOptions Update; August 22, 2014
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
August 21, 2014
07:57 EDTGILDGilead HCV risks overblown, says Bernstein
Bernstein believes that investors are concerned about upcoming competition to Gilead's (GILD) HCV drug from AbbVie's (ABBV) HCV treatment. But Bernstein says that insurers can only prevent 16% of the U.S. population from receiving Gilead's drug, and the firm does not expect the HCV market share dynamics to change in the near-term. It keeps an Outperform rating on Gilead.
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 19, 2014
16:00 EDTGILDOptions Update; August 19, 2014eBay
iPath S&P 500 VIX Short-Term Futures down 28c to 27.52. Option volume leaders: AAPL C HD PBR GILD AA NFLX TWTR TSLA EBAY according to Track Data.
09:38 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use